T

Thermo Fisher Scientific

Makes lab instruments, reagents and supplies

Inside Sales Representative - Service Portfolio

Full-Time
No salary listed
Mid
Remote in Germany+4 moreMore locations: Dreieich, Germany | Hamburg, Germany | Frankfurt, Germany | Berlin, Germany
Remote
Sales & Account ManagementAccount Executive

About the job

Responsibilities
  • Actively identify and develop new business opportunities in Germany.
  • Expand the existing customer base and systematically develop the installed customer base.
  • Strategically develop and manage a defined sales territory.
  • Implement regional growth strategies in coordination with the Sales Manager DACH.
  • Conduct customer discussions and negotiations at decision-maker level.
  • Position the product and service portfolio with clear differentiation from competitors.
  • Identify new revenue potential through cross-selling and upselling.
  • Independently manage pricing agreements, quotations, and contract renewals.
  • Develop and implement proactive strategies to maximize revenue and customer retention.
  • Maintain sales opportunities, forecasts, and the pipeline in Salesforce CRM.
  • Ensure compliance with internal pricing and approval processes.
  • Take responsibility for achieving defined revenue and growth targets.
  • Work closely with field sales, product management, marketing, and service teams.
  • Coordinate with technical specialists to position solutions optimally.
  • Cooperate with Finance, Customer Service, and Operations to process orders efficiently.
  • Support tenders and complex quotation processes.

About the company

T

Thermo Fisher Scientific

View

Thermo Fisher Scientific makes and sells the instruments, chemicals, consumables and lab services that drug companies, hospitals, universities and industrial labs use for research, testing and production. Its products cover work from gene sequencing and protein analysis to diagnostic tests and lab freezers, and its distribution arm ships supplies to labs worldwide. Drug developers also hire it to run clinical trials and to manufacture medicines under contract. It earns money from consumables that labs buy again and again, along with instrument sales, service contracts and outsourcing fees. The company traces its roots to Thermo Electron, founded in 1956, which merged with Fisher Scientific in 2006, and it is based in Waltham, Massachusetts.

Company Size

10,001+

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

1956

Get referred to Thermo Fisher Scientific

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Drugmaker demand is firming: revenue rose 10% to $11.99 billion in the June 2026 quarter, 5% excluding deals and currency.
  • Profits are outpacing sales, which supports stock grants: adjusted earnings per share rose 13% in the June 2026 quarter.
  • Career paths span many businesses: Thermo Fisher runs four segments, from diagnostics to contract drug development.

What critics are saying

  • Factory jobs are shrinking: Thermo Fisher announced in January 2026 it will close its Asheville plant, cutting 421 jobs.
  • Whole units get sold: microbiology, with $645 million in 2025 sales, went to buyout firm Astorg in August 2026.
  • Cuts reach California too: Thermo Fisher filed in January 2026 to lay off 173 Carlsbad workers by March.

What makes Thermo Fisher Scientific unique

  • Many familiar lab brands sit under one roof: Thermo Fisher owns Thermo Scientific, Applied Biosystems, Invitrogen and Fisher Scientific.
  • Thermo Fisher reaches labs through its own sales force of about 14,000 people, per its 2025 annual filing.
  • Its trial-data unit Clario has supported about 70% of FDA and EMA novel drug approvals over the past decade.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • 401(k) Retirement Plan
  • 401(k) Company Match

Company News

Yahoo Finance
Oct 22nd, 2026
Thermo Fisher Q3 revenue rises 9.1% to $12.14B, beating estimates on pharma and AI

Thermo Fisher beat Wall Street expectations in the third quarter of 2026, with sales up 9.1% year on year to $12.14 billion. Analysts had expected $11.96 billion. Adjusted earnings per share were $6.68, 4.3% above the $6.40 estimate. Operating margin rose to 18.6% from 17.5% a year earlier, and organic revenue grew 6%. Chief executive officer Marc Casper credited a broad recovery in end markets, high single-digit growth in pharma services, and strong electron microscopy demand from the semiconductor industry. Asia Pacific posted low double-digit growth. The company expects further momentum in pharma services and clinical research, and plans to integrate AI across its products. Bioscience reagents remain soft. Shares trade at $697.65, up from $687.37 before the results.

Yahoo Finance
Oct 22nd, 2026
Thermo Fisher shares rise just 1% despite Q3 revenue of $12.14B and higher guidance

Thermo Fisher Scientific shares rose about 1% after the company reported third-quarter 2026 results, a muted reaction to a clean earnings beat. Revenue reached $12.14 billion, up about 9% from $11.12 billion a year earlier, while adjusted earnings per share were $6.68. Net income, excluding extra items, rose about 7% to $1.72 billion. Adjusted operating margin expanded by 120 basis points to 24.5%, and the company raised its full-year earnings guidance. Laboratory Products & Biopharma Services grew 10% organically, with margins up 100 basis points. Organic revenue growth for 2026 is only 4%, and a planned microbiology divestiture will remove $645 million of revenue.

Yahoo Finance
Oct 21st, 2026
Thermo Fisher raises 2026 organic growth outlook to 4% on strong biopharma demand

Thermo Fisher Scientific raised its full-year organic revenue growth outlook to 4% on its third-quarter earnings call on October 21, 2026. The company said it beat its third-quarter revenue expectations and kept its fourth-quarter guidance at 4%. Chief executive officer Marc Casper said demand in pharma and biotech markets stayed strong, building on the improvement seen in the second quarter. Artificial intelligence built into its lab hardware cuts manual setup time by about 90%, Casper said. He added that the integration of Clario, a recent acquisition, is going smoothly, with revenue synergies expected as its clinical development tools join Thermo Fisher's wider offering.

CemNet
Oct 15th, 2026
Thermo Fisher launches automated XRD system.

Thermo Fisher launches automated XRD system. Published 15 October 2026, 08:33 Get daily news, weekly insights and market analysis in your inbox. Thermo Fisher Scientific has introduced the ARL X'TRA Pro X-ray diffractometer for automated mineralogical analysis in cement and mining laboratories. The system is designed for unattended operation, with capacity for up to 98 samples. According to the company, throughput ranges from 50 to more than 100 samples per day, depending on analytical requirements. Its X-ray source is rated at up to 3kW. For cement producers, X-ray diffraction supports the identification and quantification of mineral phases in raw materials, clinker and finished cement. Automated sample handling can help laboratories maintain routine analysis while reducing manual intervention. TOPICS IN THIS ARTICLE

Business Wire
Oct 6th, 2026
Thermo Fisher unveils OSD Express and expands drug development capabilities at CPHI Milan 2026

Thermo Fisher Scientific is showcasing expanded drug development and manufacturing capabilities at CPHI Milan 2026, running 6-8 October. The company is introducing OSD Express for oral solid dose development and expanding small molecule capabilities through collaboration with AustinPx, which provides access to KinetiSol Technology for improving drug bioavailability. The firm is investing in tableting, laboratory and packaging facilities across France, Canada and North America. For sterile products, new Steriles Express Solutions aim to deliver Phase I or II clinical trial material in 20 weeks. Thermo Fisher is also expanding bioprocessing capacity and clinical trial supply infrastructure, including a 52,000-square-foot facility in New York. The company is deploying generative AI to reduce master informed consent form drafting time by 50%. Thermo Fisher generates over $45 billion in annual revenue.